Cumberland Pharmaceuticals (CPIX) Debt to Equity (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Debt to Equity across 16 years of filings, most recently posting $0.25 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.25, up 33.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.25 (up 33.04% YoY), and the FY2025 annual result was $0.21, down 68.91% from the prior year.
• Debt to Equity came in at $0.25 for Q1 2026 at Cumberland Pharmaceuticals, up from $0.21 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.68 in Q4 2024 to a low of $0.18 in Q1 2025.
• The 5-year median for Debt to Equity is $0.45 (2023), against an average of $0.42.
• Across the five-year window, Debt to Equity surged 81.44% in 2024 and slumped 69.37% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Debt to Equity stood at $0.45 in 2022, then declined by 2.98% to $0.44 in 2023, then jumped by 55.08% to $0.68 in 2024, then plunged by 68.91% to $0.21 in 2025, then climbed by 16.79% to $0.25 in 2026.
• The last three Debt to Equity figures came in at $0.25 (Q1 2026), $0.21 (Q4 2025), and $0.2 (Q3 2025), per Business Quant data.